Search All Jobs
Showing 1 of 1 Jobs
Full-Time
Guardant Health
1,001-5,000 employees
Develops blood tests for cancer diagnostics
No salary listed
Expert
Hyderabad, Telangana, India
Get referrals →
You have ways to get a Guardant Health referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 11 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- 12+ years of experience in software engineering
- 3+ years in a leadership role managing multiple teams
- Hands-on experience in Full Stack or Backend development with technologies such as React, Java, and RESTful APIs
- Strong expertise in building cloud-native applications in a containerized environment (Kubernetes, AWS preferred)
- Experience with CI/CD pipelines and a strong test automation mindset
- Excellent communication and written skills
- Ability to manage distributed teams and work in a fast-paced, highly regulated environment
- Lead and mentor engineering teams, ensuring high performance, technical excellence, and career growth for team members
- Work closely with engineering leadership and cross-functional teams both in India and at our Palo Alto HQ
- Drive the technical roadmap and architecture for cloud-native applications
- Foster a strong engineering culture with an emphasis on CI/CD, test automation, and DevOps practices
- Build and maintain applications in a containerized environment (Kubernetes, AWS preferred)
- Guide teams in Full Stack and Backend development using React, Java, and RESTful APIs
- Ensure high code quality, reliability, and test automation to meet regulatory and business requirements
- Prior experience in the Life Sciences industry
- Experience working with Laboratory Information Management Systems (LIMS), LabVantage preferred
- Familiarity with regulated environments such as HIPAA
Guardant Health specializes in blood-based tests that provide essential information for cancer treatment and management. Their products are designed to assist patients at various stages of cancer, from early detection to managing advanced disease. The company develops and sells diagnostic tests that utilize blood samples to detect, monitor, and guide treatment decisions for cancer patients. Their main product, Guardant360, is FDA-approved and commonly used to help inform treatment choices for those with advanced cancer. Guardant Health is also working on expanding its offerings to include tests for early-stage cancer detection and monitoring for recurrence. By focusing on non-invasive diagnostics that provide rich data, Guardant Health aims to enhance patient outcomes and lessen the overall impact of cancer.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2012
Simplify's Take
What believers are saying
- Partnerships with Pfizer and ConcertAI enhance research and therapy development capabilities.
- Growing demand for liquid biopsy tests supports Guardant Health's market expansion.
- FDA approvals bolster credibility and adoption of Guardant Health's diagnostic solutions.
What critics are saying
- Increased competition from companies like Natera may erode market share.
- Dependency on key partnerships, like with Pfizer, poses revenue concentration risks.
- Challenges in early-stage cancer detection expansion may delay revenue growth.
What makes Guardant Health unique
- Guardant Health specializes in non-invasive, blood-based cancer diagnostics.
- The company offers FDA-approved tests like Guardant360 for advanced cancer treatment decisions.
- Guardant Health integrates AI and real-world data for precision oncology solutions.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%NEW YORK - Guardant Health said Thursday that it has entered a multiyear strategic collaboration with Pfizer, under which it will support the development and commercialization of cancer therapies using its Guardant Infinity liquid biopsy platform.
Guardant Health, a leading precision oncology company, has entered into a collaboration with ConcertAI, an oncology real-world evidence (RWD) data and AI technology company.
What You Should Know:– Guardant Health, a provider in precision oncology, and ConcertAI, a real-world evidence (RWE) and AI technology company in oncology, announced a strategic collaboration that will provide biopharmaceutical companies with access to a first-of-its-kind multi-modal real-world data (RWD) solution.– The partnership integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling information, offering a deeper understanding of cancer biology and treatment response.Enhanced Cancer Research and DevelopmentCancer is a complex disease, and a patient’s response to treatment can be influenced by various factors, including specific genetic mutations, prior therapies, and the development of drug resistance. This new joint RWD solution provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This allows biopharma researchers to:Better interpret disease biology: Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression.Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression. Identify drivers of tumor evolution: Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread.Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread. Understand resistance mechanisms: Uncover how tumors develop resistance to therapies, both intrinsically and over time.By leveraging this comprehensive dataset, combined with the analytics capabilities and AI SaaS solutions of both ConcertAI and Guardant Health, biopharmaceutical companies can gain a deeper understanding of cancer and develop more effective treatments.“Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment and the patient’s response to therapy,” said Helmy Eltoukhy, Guardant Health co-CEO. “This partnership between Guardant and ConcertAI gives evidence and outcomes researchers access to extensive, robust data and AI-based modeling that can provide unprecedented insight into a patient’s cancer journey, including a tumor’s complex systemic interactions, to help them accelerate the development of much-needed cancer therapies
PALO ALTO, Calif.-(BUSINESS WIRE)- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, has announced a new partnership with precision oncology company Guardant Health Inc. (Nasdaq: GH).